ALC Kinetics Velocity and Acceleration Are Early Predictors of Non-Icans Neurotoxicities after Cilta-Cel Treatment
Yein Jeon(University of Washington Medical Center), Jordan Gauthier(Seattle Cancer Care Alliance), Rahul Banerjee(University of Washington), Danai Dima(Fred Hutch Cancer Center), Andrew J. Portuguese(University of Washington), Christy Khouderchah(University of Washington), Alexandre V. Hirayama(University of Washington), Meredith Durbin, Jennifer J. Huang(Stanford Medicine), Xiancheng Wu, Lawrence Fong(University of Washington), Mazyar Shadman(University of Washington), Emily C. Liang, Qian Vicky Wu(Fred Hutch Cancer Center), Erik L. Kimble(University of Washington)
Cited by 0
Related Papers
Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma
|Blood|2017|217
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies
|Blood|2020|217
Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy
|Transplantation and Cellular Therapy|2023|144